Various genes implicated in the PPGL pathogenesis, their impact on the tumorigenesis and the functional imaging specific to the cluster types
Cluster type | Sub-type | Germline or somatic | Exclusively somatic | Location of gene | Normal function | Impact of mutations | Nuclear imaging |
---|---|---|---|---|---|---|---|
Pseudohypoxia | Cluster 1A | SDHA SDHB SDHC SDHD SDHAF2 FH MDH2 IDH3B GOT2 DLST SLC25A11 SUCLG2 | IDH1 IDH2 | 5p15 1p36.1-p35 1q23.3 11q23.1 11q12.2 1q42.1 7q11.23 20p13 16q21 14q24.3 17p13.2 3p14.1 2q34 15q26.1 | Regulate oxygen levels and HIF activity | HIF accumulation, propelling angiogenesis, and tumor expansion | 68Ga-DOTATATE positron emission tomography/computed tomography (PET/CT) |
Cluster 1B | VHL EGLN1 EGLN2 | EPAS1 | 3p25.3 1q42.2 19q13.2 2p21 | Regulate oxygen levels and HIF activity | HIF accumulation, propelling angiogenesis, and tumor expansion | 18F-FDOPA imaging | |
Kinase signaling | Cluster 2A and 2B | NF1 RET MAX TMEM127 MET MERTK | FGFR1 HRAS BRAF | 17q11.2 10q11.21 14q23.3 2q11.2 7q31 2q14.1 8p11.23 11p15.5 7q34 | Control cell growth and proliferation | Cell proliferation, differentiation, and apoptosis | 18F-FDOPA imaging |
Wnt signaling | None | None | CSDE1 UBTF-MAML3 | 1p13.3 4q31.3 | Regulate cellular differentiation and proliferation | Anomalous cell differentiation and tumorigenesis | None |
GOT2: glutamic-oxaloacetic transaminase 2; DLST: dihydrolipoamide succinyltransferase; SLC25A11: solute carrier family 25 member 11; SUCLG2: succinate-CoA ligase GDP-forming subunit beta 2; MET: mesenchymal-epithelial transition factor; MERTK: myeloid-epithelial-reproductive tyrosine kinase; FGFR1: fibroblast growth factor receptor 1; HRAS: Harvey rat sarcoma viral oncogene homolog; BRAF: B-type Raf kinase; UBTF: upstream binding transcription factor; 68Ga-DOTA-TATE: 68Gallium-DOTA-Tyr3-octreotate; 18F-FDOPA: 6-L-18F-fluorodihydroxyphenylalanine
MSJ and NM: Resources, Writing—original draft, Writing—review & editing. CFJ and JMP: Conceptualization, Supervision, Writing—review & editing. All authors read and approved the submitted version.
The authors declare that they have no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
© The Author(s) 2024.